Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Invokana Adds Warnings On Amputation Risk, But Will It Give Jardiance An Edge?

Executive Summary

New data from J&J's cardiovascular outcomes trials shows leg and foot amputations occurred about twice as often in diabetes patients treated with canagliflozin versus placebo.

You may also be interested in...



Keeping Track: Flexion's Non-Opioid Knee Pain Drug Gets OK, Botox Gets Another Approval

The latest drug development news and highlights from our Performance Tracker.

CANVAS Trial Results: Better For Janssen, Lilly Or the SGLT2 Class?

Janssen's Invokana reduced cardiovascular events in CANVAS on par with the MACE reduction in Lilly's and Boehringer's EMPA-REG trial for competing SGLT2 inhibitor Jardiance, but the CV benefit comes with a doubling of amputation risk versus placebo.

J&J Plots Five-Year Pharma Growth Plan Around Mega-Brands And Launches

Management outlined how the company plans to achieve above-market compound-annual growth from 2016 to 2021 during an R&D Day near its New Jersey headquarters.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS120659

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel